Vitamin D levels and menopause-related symptoms.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

The study group was 1,407 women.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

A randomly selected subset of 1,407 women, among 26,104 potentially eligible participants of the Women's Health Initiative Calcium and Vitamin D trial of postmenopausal women aged 51 to 80 years, had 25-hydroxyvitamin D [25(OH)D] levels measured at the Women's Health Initiative Calcium and Vitamin D trial baseline visit.

Information about menopause-related symptoms at baseline was obtained by questionnaire and included overall number of symptoms and composite measures of sleep disturbance, emotional well-being, and energy/fatigue, as well as individual symptoms.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

After exclusions for missing data, 530 women (mean [SD] age, 66.2 [6.8] y) were included in these analyses.

What Was Measured

The subject headings attached to it are Calcium, Calcium, Dietary, Cross-Sectional Studies, Dietary Supplements, Emotions, Exercise and Fatigue.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 1,407 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Menopause (New York, N.Y.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.